Boehringer Ingelheim Venture Fund co-led a $13.3m round for the immuno-oncoclogy startup, which was spun out of University of Duisburg-Essen’s and University of Düsseldorf.

Germany-based cancer immunotherapy developer Abalos Therapeutics launched yesterday with €12m ($13.3m) in funding from a series A round co-led by pharmaceutical firm Boehringer Ingelheim. Venture capital fund Gründerfonds Ruhr co-led the round, which included public-private partnership High-Tech Gründerfonds and NRW.Bank, the state development bank of North Rhine-Westphalia. Boehringer Ingelheim invested through its Boehringer Ingelheim Venture…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.